The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis

Woolley, Stephen, Duru, Iheukwumere, Pagano, Luca, Lester, Rebecca, Devine, Karen, Ahmad, Shazaad, Huq, Raqib, Marshall, Suzanne, McLaughlan, Danielle, Lavery, Mark, Challenger, Elizabeth, Else, Laura J, Semple, Malcolm G, Kaye, Stephen, Khoo, Saye H and Beadsworth, Mike (2025) 'The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis'. The Journal of Antimicrobial Chemotherapy. (In Press)

Text dkaf071.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (226kB)

Abstract

Mpox is an orthopox DNA virus.1,2 Ophthalmic manifestations include preseptal cellulitis, conjunctivitis and keratitis, either as a primary or secondary viral infection or a secondary bacterial infection.2 Tecovirimat (Tpoxx) is an oral orthopox-specific drug that inhibits the orthopoxvirus VP37 envelope-wrapping protein and prevents the formation of egress-competent virions.3 There are limited pharmacokinetic/pharmacodynamic (PK/PD) data available. We present a case report of a critically unwell mpox patient, who had tecovirimat PK sampling of plasma and tears.

Item Type:	Article
Subjects:	QV Pharmacology > QV 38 Drug action. WC Communicable Diseases > Virus Diseases > Infectious Viral Skin Diseases > WC 570 Infectious viral skin diseases
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1093/jac/dkaf071
SWORD Depositor:	JISC Pubrouter
Depositing User:	JISC Pubrouter
Date Deposited:	02 Apr 2025 10:44
Last Modified:	02 Apr 2025 10:44
URI:	https://archive.lstmed.ac.uk/id/eprint/26474

Statistics

View details

Actions (login required)

Edit Item